Stage IA2 squamous lung cancer: lung-sparing segmentectomy after COPD optimization

Patient Info: Anonymized, Male, 70+

Biomarkers: Squamous lung cancer markers present; PD-L1 TPS 10%, EGFR IHC present

At 18 months after lung-sparing VATS segmentectomy, he had good quality of life, no dyspnea or chronic cough, and surveillance imaging showed no recurrence.

PubMed CentralRead more →

Stage IIB lung adenocarcinoma: pembrolizumab-associated psoriasiform dermatitis resolved after stopping therapy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: PD-L1 status not reported in the available case text

Over 3 years of follow-up after stopping pembrolizumab, the psoriasiform dermatitis resolved completely and lung adenocarcinoma remained stable without radiologic or serologic recurrence.

PubMed CentralRead more →

Targeted therapy made Stage III ALK-positive lung cancer operable

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ALK-positive; PD-L1 high

Surgery found no residual cancer, and follow-up scans showed no recurrence through 15 months.

PubMed CentralRead more →

Stage I EGFR Lung Cancer: Shira's Survivor Story

Patient Info: Shira, Female | Stage I

Biomarkers: EGFR exon 20 insertion

Shira had Stage IB lung cancer detected early through imaging and treated with surgery alone. Her tumor was later categorized as low risk of recurrence, and she described herself as cancer-free as of February 2026.

The Patient StoryRead more →

Prior Stage IA lung adenocarcinoma with fungal airway disease mimicking recurrence

Patient Info: Anonymized, Female, 70+ | Stage I

Her prior Stage IA lung adenocarcinoma was surgically treated without adjuvant therapy, and later pulmonary lesions were attributed to allergic bronchopulmonary mycosis rather than cancer recurrence; symptoms and imaging improved after antifungal and inhaled therapy.

PubMed CentralRead more →

Pulmonary epithelioid hemangioendothelioma with complete response after neoadjuvant therapy

Patient Info: Anonymized, Male, 60s

Biomarkers: WWTR1-CAMTA1 fusion; vascular markers supported epithelioid hemangioendothelioma; lung cancer markers were absent.

The patient achieved radiographic disappearance of the lung tumor after neoadjuvant paclitaxel/carboplatin plus bevacizumab. Surgery then showed no residual tumor and lymph nodes were negative; CT follow-up through April 2024 showed no recurrence.

PubMed CentralRead more →

Locally advanced lung adenocarcinoma: neoadjuvant treatment, surgery, and fistula repair

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Three months after reconstruction for postoperative esophagopleural fistula, her nutritional status had improved and esophagogram showed no anastomotic leak; long-term lung cancer control was not reported.

PubMed CentralRead more →

Stage I Lung Cancer: Taylor's Survivor Story

Patient Info: Taylor, Female, Under 40 | Stage I

Taylor had a Stage IB 4 cm lung carcinoid tumor removed surgically with clean margins at age 21. She did not need chemotherapy or radiation and was 18 years post-diagnosis as of February 2026.

The Patient StoryRead more →

Lung Cancer Treated With Sleeve Right Lower Lobectomy in COPD — Case 4

Patient Info: Anonymized, male | Stage II

He had no lung-cancer recurrence and died from a cerebral hemorrhage 51 months after surgery.

PubMed CentralRead more →

Lung Cancer Treated With Sleeve Right Lower Lobectomy in COPD

Patient Info: Anonymized, male | Stage II

He remained disease-free through 28 months of follow-up.

PubMed CentralRead more →

Lung Cancer Treated With Sleeve Right Lower Lobectomy in COPD — Case 2

Patient Info: Anonymized, male | Stage I

He remained disease-free through 26 months of follow-up.

PubMed CentralRead more →

Lung Cancer Treated With Sleeve Right Lower Lobectomy in COPD — Case 3

Patient Info: Anonymized, male | Stage II

He remained disease-free through 30 months of follow-up.

PubMed CentralRead more →

Early lung adenocarcinoma found on screening with surgical recovery after tamponade complication

Patient Info: Anonymized, Male, 60s | Stage I

The Stage I lung adenocarcinoma was removed by wedge resection with clear margins. A life-threatening postoperative cardiac tamponade was successfully treated, and the patient was discharged on postoperative day 19 with full recovery.

PubMed CentralRead more →

Stage IV ALK Lung Cancer: Ruchira's Survivor Story

Patient Info: Ruchira, Female | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Not reported

Although the disease progressed to Stage IV after lobectomy, ALK testing led to lorlatinib; she reported no evidence of disease after 3 months and continued daily targeted therapy.

The Patient StoryRead more →

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed CentralRead more →

Lynch-associated lung and colorectal cancers responded to immunotherapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: dMMR/MSI-H pattern with MLH1/PMS2 loss and germline MLH1 mutation; KRAS and PTEN mutations; PD-L1 TPS 15%.

Metastatic Site: right paraspinal metastatic lesion from lung…

After starting iparomlimab plus tuvonralimab, pleural and pelvic disease improved, intestinal wall involvement decreased further after 5 cycles, the paraspinal lung metastasis remained stable, tumor markers stayed normal, and treatment continued.

PubMed CentralRead more →

Lung cancer treated with nivolumab: rare kidney inflammation as a side effect

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: lung; pleura; lymph nodes

He remained dependent on maintenance hemodialysis after the kidney injury and died from advanced lung cancer 10 months later.

PubMed CentralRead more →

Stage IA primary mucinous lung adenocarcinoma with enteric differentiation in a patient with CLL/SLL

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: Lung tumor markers supported mucinous adenocarcinoma with enteric features. CLL/SLL markers were present in lymph nodes, not lung metastasis.

As of January 2026, he remained free of lung cancer for 24 months after thoracoscopic wedge resection of localized Stage IA primary mucinous lung adenocarcinoma, while CLL/SLL continued to be managed separately.

PubMed CentralRead more →

ALK-positive inflammatory myofibroblastic lung tumor: surgery and 2-year recurrence-free surveillance

Patient Info: Anonymized, Female, 60s

Biomarkers: ALK-1-positive; TPM4-ALK rearrangement; TP53 missense variant VAF 2.3%; DNMT3A frameshift mutation VAF 2.3%

She remained stable without recurrence for 2 years after complete surgical resection of an ALK-positive inflammatory myofibroblastic tumor of the lung.

PubMed CentralRead more →

MET exon 14 skipping lung adenocarcinoma: sequential MET-TKI toxicity and ongoing chemotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; EGFR negative; ALK negative; ROS1 negative; PD-L1 tumor proportion score 10%

Metastatic Site: pleura

The cancer recurred with pleural dissemination after surgery and adjuvant UFT. Sequential MET inhibitors and systemic therapies provided periods of disease control but were limited by ILD and non-ILD toxicities; at the report, he remained on carboplatin, pemetrexed, and bevacizumab.

PubMed CentralRead more →

Lung Cancer: Regina's Survivor Story

Patient Info: Regina, Female, 40s

Regina reported being cancer-free after surgical removal of a rare neuroendocrine lung tumor, while living with reduced lung capacity, survivor guilt, fear of recurrence, and medical PTSD.

The Patient StoryRead more →

Stage IIIA KRAS/STK11/TP53-mutated lung adenocarcinoma: fatal pembrolizumab-induced myocarditis after adjuvant therapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Ki-67 20-25%; PD-L1 expression 10%; KRAS exon 2 mutation; STK11 mutation; TP53 mutation

As of December 2025, he had died after 15 days of hospitalization from sepsis and multi-organ failure following severe pembrolizumab-induced myocarditis after adjuvant treatment for resected Stage IIIA lung adenocarcinoma.

PubMed CentralRead more →

Stage IV Pulmonary Lymphoepithelioma-Like Cancer With Pseudoprogression After Immunotherapy and Radiation

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: EBER positive; no EGFR, ROS1, RAS/RAF or PIK3CA mutations/fusions detected

Through May 2025, follow-up showed no clear evidence of cancer recurrence or metastasis, with progression-free survival exceeding 70 months.

PubMed CentralRead more →

Stage IVB SMARCA4-deficient NSCLC with brain metastasis: stable disease after surgery, radiation, chemotherapy, immunotherapy, and bevacizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: SMARCA4/BRG-1 loss with TP53 and other mutations; TMB high; PD-L1 <1%; MSI-H not detected.

Metastatic Site: brain

As of October 2025, the patient had stable disease, no brain recurrence, a controlled left lower-lobe lung lesion, and manageable treatment toxicity while continuing bevacizumab plus pemetrexed maintenance.

PubMed CentralRead more →